Effect of SGLT2 inhibitors on mean platelet volume in heart failure with reduced ejection fraction: a real-world analysis independent of diuretic therapy
Open Access
- 23 June 2026
- journal article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (6) , 2133-2139
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as cornerstone therapies for heart failure with reduced ejection fraction (HFrEF), owing to their cardioprotective and hematologic effects. While their impact on hemoglobin and hematocrit levels is increasingly recognized, the influence of SGLT2 inhibitors on mean platelet volume (MPV), a surrogate marker of platelet activation and cardiovascular risk, remains underexplored in HFrEF patients. While SGLT2 inhibitors’ effects on MPV have been studied in DM, this is the first study examining MPV changes specifically in HFrEF patients with adjustment for diuretic therapy. This retrospective study included 80 HFrEF patients receiving guideline-directed medical therapy to which SGLT2 inhibitors were subsequently added. Baseline and 6-month follow-up data on hematological and biochemical parameters were collected. Exclusion criteria included active infection, malignancy, advanced renal failure, hematologic disorders, and recent transfusions. MPV and platelet counts were analyzed using standardized protocols and equipment. Following 6 months of SGLT2 inhibitor therapy, MPV values decreased significantly ( p < 0.05), while platelet counts increased significantly ( p < 0.05). Although hemoglobin and hematocrit levels showed upward trends, these changes were not statistically significant. No significant correlation was observed between ΔMPV and ΔPLT. Other biochemical markers remained stable throughout the study period. SGLT2 inhibitor therapy was associated with a significant reduction in MPV and an increase in platelet count among patients with HFrEF. These hematological changes may represent an additional mechanism by which SGLT2 inhibitors exert cardiovascular benefit. However, prospective, randomized trials are needed to validate these findings and explore the clinical significance of MPV modulation in heart failure management.Keywords
Funding Information
- Tekirdağ Namık Kemal Üniversitesi
This publication has 19 references indexed in Scilit:
- Mean platelet volume and cardiovascular outcomes in patients with coronary heart disease: A meta-analysis of prospective studiesMedicine, 2026
- SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug typeAtherosclerosis, 2023
- Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2022
- Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysisClinical Research in Cardiology, 2021
- Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitusDiabetologia, 2021
- Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes MellitusClinical Pharmacology & Therapeutics, 2009
- Seasonal changes in platelets, fibrinogen and factor VII in elderly peopleAge and Ageing, 2003
- Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery diseaseBritish Journal of Haematology, 2002
- Platelet sizeBlood Coagulation & Fibrinolysis, 1996